Rodino-Klapac Louise has filed 37 insider transactions across 1 company since March 2024.
Most recent transaction: a tax payment of 948 shares of Sarepta Therapeutics, Inc. ($SRPT) on March 11, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | F | Common Stock | 948 | $17.03 | 225,323.0000 | 100,237,000 | 0.42% | 0.00% |
| March 9, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | F | Common Stock | 895 | $16.95 | 226,271.0000 | 100,237,000 | 0.39% | 0.00% |
| March 9, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | F | Common Stock | 504 | $16.95 | 227,166.0000 | 100,237,000 | 0.22% | 0.00% |
| March 1, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | M | Common Stock | 8125 | $0.00 | 232,155.0000 | 100,237,000 | 3.63% | 0.01% |
| March 1, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | M | Performance Stock Units | 8125 | $0.00 | 0.0000 | 100,237,000 | 100.00% | 0.01% |
| March 2, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | F | Common Stock | 767 | $16.20 | 227,670.0000 | 100,237,000 | 0.34% | 0.00% |
| March 2, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | F | Common Stock | 3718 | $16.20 | 228,437.0000 | 100,237,000 | 1.60% | 0.00% |
| Feb. 25, 2026 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | A | Performance Stock Units | 1875 | $0.00 | 8,125.0000 | 100,237,000 | 30.00% | 0.00% |
| Nov. 17, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | F | Common Stock | 4582 | $18.42 | 224,030.0000 | 100,237,000 | 2.00% | 0.00% |
| Sept. 3, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | A | Common Stock | 50000 | $0.00 | 228,612.0000 | 107,875,000 | 27.99% | 0.05% |
| Sept. 3, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | A | Common Stock | 93875 | $0.00 | 178,612.0000 | 107,875,000 | 110.78% | 0.09% |
| Aug. 5, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | President, R&D and Tech Ops | A | Performance Stock Units | 6250 | $0.00 | 6,250.0000 | 107,875,000 | 9999.99% | 0.01% |
| March 10, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | A | Stock Options (right to buy) | 16644 | $0.00 | 16,644.0000 | 107,875,000 | 9999.99% | 0.02% |
| March 7, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | M | Common Stock | 5500 | $0.00 | 79,818.0000 | 107,875,000 | 7.40% | 0.01% |
| March 10, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 924 | $100.13 | 78,894.0000 | 107,875,000 | 1.16% | 0.00% |
| March 10, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 2539 | $100.13 | 76,355.0000 | 107,875,000 | 3.22% | 0.00% |
| March 10, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | A | Common Stock | 8276 | $0.00 | 84,631.0000 | 107,875,000 | 10.84% | 0.01% |
| March 7, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | M | Performance Stock Units | 5500 | $0.00 | 0.0000 | 107,875,000 | 100.00% | 0.01% |
| March 6, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | M | Performance Stock Units | 17500 | $0.00 | 0.0000 | 107,875,000 | 100.00% | 0.02% |
| March 6, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | M | Common Stock | 17500 | $0.00 | 82,822.0000 | 107,875,000 | 26.79% | 0.02% |
| March 7, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 514 | $103.70 | 82,308.0000 | 107,875,000 | 0.62% | 0.00% |
| March 7, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 7990 | $103.70 | 74,318.0000 | 107,875,000 | 9.71% | 0.01% |
| March 4, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 1704 | $101.34 | 65,322.0000 | 107,875,000 | 2.54% | 0.00% |
| March 3, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 715 | $103.77 | 67,026.0000 | 107,875,000 | 1.06% | 0.00% |
| Feb. 11, 2025 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | A | Performance Restricted Stock Units | 3500 | $0.00 | 17,500.0000 | 107,875,000 | 25.00% | 0.00% |
| Nov. 18, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 4558 | $102.89 | 67,630.0000 | 100,448,000 | 6.31% | 0.00% |
| June 21, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | M | Performance Stock Units | 6250 | $0.00 | 0.0000 | 92,398,000 | 100.00% | 0.01% |
| June 21, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | A | Performance Stock Units | 6250 | $0.00 | 6,250.0000 | 92,398,000 | 9999.99% | 0.01% |
| June 21, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | A | Performance Stock Units | 5500 | $0.00 | 5,500.0000 | 92,398,000 | 9999.99% | 0.01% |
| June 24, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 2182 | $164.64 | 72,141.0000 | 92,398,000 | 2.94% | 0.00% |
| June 21, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | M | Common Stock | 6250 | $0.00 | 74,323.0000 | 92,398,000 | 9.18% | 0.01% |
| March 8, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 909 | $123.14 | 68,073.0000 | 92,398,000 | 1.32% | 0.00% |
| March 7, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 512 | $120.49 | 68,982.0000 | 92,398,000 | 0.74% | 0.00% |
| March 4, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 1728 | $125.32 | 69,494.0000 | 92,398,000 | 2.43% | 0.00% |
| March 1, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | F | Common Stock | 778 | $126.19 | 65,222.0000 | 92,398,000 | 1.18% | 0.00% |
| March 1, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 92,398,000 | 9999.99% | 0.01% |
| March 1, 2024 | Sarepta Therapeutics, Inc. | $SRPT | Rodino-Klapac Louise | Head of R&D, CSO | A | Common Stock | 6000 | $0.00 | 71,222.0000 | 92,398,000 | 9.20% | 0.01% |